

Helsinki, 20 October 2020

Addressees

Registrants of Joint submission 12767-90-7 listed in the last Appendix of this decision

Date of submission for the jointly submitted dossier subject of a decision

20/08/2019

Registered substance subject to this decision, hereafter 'the Substance'

Substance name: Hexaboron dizinc undecaoxide

EC number: 235-804-2

CAS number: 12767-90-7

Decision number: [Please refer to the REACH-IT message which delivered this communication (in format TPE-D-XXXXXXXXXX-XX-XX/F)]**DECISION ON A TESTING PROPOSAL**

Based on Article 40 of Regulation (EC) No 1907/2006 (REACH), ECHA requests that you submit the information listed below by the deadline of **25 January 2022**.

Requested information must be generated using the Substance unless otherwise specified.

A. Requirements applicable to all the Registrants subject to Annex VIII of REACH

1. In vivo mammalian erythrocyte micronucleus test (Annex VIII, Section 8.4., column 2; test method: OECD TG 474) in mice or rats, oral route.

Conditions to comply with the requests

Each addressee of this decision is bound by the requests for information corresponding to the REACH Annexes applicable to their own registered tonnage of the Substance at the time of evaluation of the jointly submitted dossier.

To identify your legal obligations, please refer to the following:

- you have to comply with the requirements of Annexes VII and VIII of REACH, if you have registered a substance at 10-100 tpa;
- you have to comply with the requirements of Annexes VII to IX of REACH, if you have registered a substance at 100-1000 tpa;
- you have to comply with the requirements of Annexes VII to X of REACH, if you have registered a substance at above 1000 tpa.

Registrants are only required to share the costs of information they are required to submit to fulfil the information requirements for their registration.

The Appendix A states the reasons for the request for information to fulfil the requirement set out in the Annex of REACH.

The Appendix entitled Observations and technical guidance addresses the generic approach for the selection and reporting of the test material used to perform the required studies and provides generic recommendations and references to ECHA guidance and other reference documents.

You must submit the information requested in this decision by the deadline indicated above in an updated registration dossier and also update the chemical safety report, where relevant, including any changes to classification and labelling, based on the newly generated information.

Appeal

This decision can be appealed to the Board of Appeal of ECHA within three months of its notification. An appeal, together with the grounds thereof, has to be submitted to ECHA in writing. An appeal has suspensive effect and is subject to a fee. Further details are described under: <http://echa.europa.eu/regulations/appeals>.

Approved¹ under the authority of Christel Schilliger-Musset, Director of Hazard Assessment

¹ As this is an electronic document, it is not physically signed. This communication has been approved according to ECHA's internal decision-approval process.

Appendix A: Reasons for the requirements applicable to all the Registrants subject to Annex VIII of REACH

This decision is based on the examination of the testing proposals you submitted.

1. In vivo mammalian erythrocyte micronucleus test (Annex VIII, Section 8.4., column 2)

Under Annex VIII Section 8.4., column 2 of REACH, the performance of an appropriate *in vivo* somatic cell genotoxicity study must be considered if there is a positive result in any of the *in vitro* genotoxicity studies in Annex VII or VIII.

Your dossier contains positive results for the *in vitro* cytogenicity test in mammalian cells with the Substance which raises the concern for chromosomal aberrations. Therefore, you submitted a testing proposal for an *in vivo* mammalian erythrocyte micronucleus test to be performed with the Substance.

ECHA requested your considerations for alternative methods to fulfil the information requirement for Genetic toxicity *in vivo*. ECHA notes that you provided your considerations concluding that there were no alternative methods which could be used to adapt the information requirement(s) for which testing is proposed. ECHA has taken these considerations into account.

ECHA agrees that an appropriate *in vivo* follow up genotoxicity study is necessary to address the concern identified *in vitro*.

i. Test selection

ECHA notes that the proposed test is appropriate to further investigate effects on chromosomal aberrations *in vivo*².

According to the ECHA Guidance Chapter R.7a³, the mammalian erythrocyte micronucleus test ("MN test", OECD TG 474 is suitable to follow-up a positive *in vitro* result on chromosomal aberration if the Substance or its metabolite(s) will reach the target tissue.

ii. Test design

You did not specify the species to be used for testing. You did not specify the route for testing.

According to the test method OECD TG 474, the test must be performed in mice or rats. Having considered the anticipated routes of human exposure and the need for adequate exposure of the target tissue(s) performance of the test by the oral route is appropriate.

Regarding the exposure of the target tissue, the applicable test guideline (OECD TG 474) states "If there is evidence that the test substance(s), or its metabolite(s), will not reach the target tissue, it may not be appropriate to use this test". Additionally, a negative test result can be considered reliable if "Bone marrow exposure to the test substance(s) occurred". Accordingly, if the Substance is negative in this test, but it is not possible to demonstrate that bone marrow exposure to the Substance occurred, then ECHA will consider any remaining uncertainty concerning the mutagenic potential of the Substance and whether to request any further information.

² ECHA Guidance R.7a, Section R.7.7.6.3. and Figure R.7.7-1

³ ECHA Guidance Chapter R.7a, Section R.7.7.6.3

iii. Germ cells

You may consider to collect male gonadal cells (spermatogonia) at the same time as the other tissues, in order to limit additional animal testing. You can prepare the slides for male gonadal cells and store them for several months at room temperature, in dry conditions and protected from light. Following the generation and analysis of data on somatic cells, you should consider analysing the slides prepared with spermatogonia, using the mammalian spermatogonial chromosome aberration test (OECD TG 483). This type of evidence may be relevant for the overall assessment of possible germ cell mutagenicity including classification and labelling according to the CLP Regulation.

iv. Outcome

Under Article 40(3)(a) of REACH, you are requested to carry out the proposed test with the Substance:

In vivo mammalian erythrocyte micronucleus test (test method: OECD TG 474) in mice or rats, oral route.

Appendix B: Procedural history

ECHA started the testing proposal evaluation in accordance with Article 40(1) on 10 October 2019.

ECHA held a third party consultation for the testing proposals from 25 November 2019 until 9 January 2020. ECHA did not receive information from third parties.

For the purpose of the decision-making, this decision does not take into account any updates of registration dossiers after the date on which you were notified the draft decision according to Article 50(1) of REACH.

The decision making followed the procedure of Article 51 of the REACH Regulation, as described below:

ECHA notified you of the draft decision and invited you to provide comments.

ECHA did not receive any comments within the notification period.

ECHA notified the draft decision to the competent authorities of the Member States for proposals for amendment.

As no amendments were proposed, ECHA adopted the decision under Article 51(3) of REACH.

Appendix C: Observations and technical guidance

1. This testing proposal examination decision does not prevent ECHA from initiating compliance checks at a later stage on the registrations present.
2. Failure to comply with the requests in this decision, or to otherwise fulfil the information requirements with a valid and documented adaptation, will result in a notification to the enforcement authorities of your Member State(s).
3. Test guidelines, GLP requirements and reporting
Under Article 13(3) of REACH, all new data generated as a result of this decision needs to be conducted according to the test methods laid down in a European Commission Regulation or according to international test methods recognised by the Commission or ECHA as being appropriate.

Under Article 13(4) of REACH, ecotoxicological and toxicological tests and analyses must be carried out according to the GLP principles (Directive 2004/10/EC) or other international standards recognised by the Commission or ECHA.

Under Article 10 (a) (vi) and (vii) of REACH, all new data generated as a result of this decision must be reported as study summaries, or as robust study summaries, if required under Annex I of REACH. See ECHA Practical Guide: 'How to report robust study summaries'⁴.

4. Test material
Selection of the test material(s)
The registrants of the Substance are responsible for agreeing on the composition of the test material to be selected for carrying out the tests required by the present decision. The test material selected must be relevant for all the registrants of the Substance, i.e. it takes into account the variation in compositions reported by all members of the joint submission. The composition of the test material(s) must fall within the boundary composition(s) of the Substance.

While selecting the test material you must take into account the impact of each constituent/impurity is known to have or could have on the test results for the endpoint to be assessed. For example, if a constituent/impurity of the Substance is known to have an impact on (eco)toxicity, the selected test material must contain that constituent/impurity.

Technical reporting of the test material

The composition of the selected test material must be reported in the respective endpoint study record, under the Test material section. The composition must include all constituents of the test material and their concentration values. Without such detailed reporting, ECHA may not be able to confirm that the test material is relevant for the Substance and to all the registrants of the Substance.

Technical instructions are available in the manual "How to prepare registration and PPORD dossiers"⁵.

⁴ <https://echa.europa.eu/practical-guides>

⁵ <https://echa.europa.eu/manuals>

5. List of references of the ECHA Guidance and other guidance/ reference documents⁶
QSARs, read-across and grouping

Guidance on information requirements and chemical safety assessment, Chapter R.6 (version 1.0, May 2008), referred to as ECHA Guidance R.6 in this decision.

ECHA Read-across assessment framework (RAAF, March 2017)⁷

Toxicology

Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7c (version 3.0, June 2017), referred to as ECHA Guidance R.7c in this decision.

Environmental toxicology and fate

Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7b (version 4.0, June 2017), referred to as ECHA Guidance R.7b in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7c (version 3.0, June 2017), referred to as ECHA Guidance R.7c in this decision.

PBT assessment

Guidance on information requirements and chemical safety assessment, Chapter R.11 (version 3.0, June 2017), referred to as ECHA Guidance R.11 in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.16 (version 3.0, February 2016), referred to as ECHA Guidance R.16 in this decision.

OECD Guidance documents

Guidance Document on aqueous-phase aquatic toxicity testing of difficult test chemicals – No 23, referred to as OECD GD 23.

Guidance Document on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption – No 150, referred to as OECD GD 150.

⁶ <https://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment>

⁷ <https://echa.europa.eu/support/registration/how-to-avoid-unnecessary-testing-on-animals/grouping-of-substances-and-read-across>

Appendix D: List of the registrants to which the decision is addressed and the corresponding information requirements applicable to them

Registrant Name	Registration number	(Highest) Data requirements to be fulfilled
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

Note: where applicable, the name of a third party representative (TPR) may be displayed in the list of recipients whereas the decision is sent to the actual registrant.